Novartis inaugurates $90m cell and gene therapies facility in Stein
Novartis will manufacture Kymriah and other CAR-T cell therapies and gene therapies at the new factory
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
29 Nov 19
Novartis will manufacture Kymriah and other CAR-T cell therapies and gene therapies at the new factory
29 Nov 19
The FDA has accepted AstraZeneca’s sBLA for Imfinzi based on positive results from the phased III CASPIAN trial
28 Nov 19
The acquisition forms part of Asahi Kasei’s plan to accelerate its transformation into a global healthcare company
26 Nov 19
FerGene, a new gene therapy firm, will be established as a subsidiary of Ferring, to commercialise bladder cancer…
19 Nov 19
Novo Nordisk will pay $175m as upfront payment, $50m as an equity investment in Dicerna at a premium,…
14 Nov 19
The pivotal phase 3 study is a randomised, double-blind, placebo-controlled study that enrolled 108 patients to investigate the…
13 Nov 19
The merger would provide an expanded geographic reach for the new company Viatris’ wide-ranging product portfolio and future…
05 Nov 19
Boehringer Ingelheim and Eli Lilly have been developing and commercialising Trajenta (linagliptin) and Basaglar (insulin glargine)
31 Oct 19
The collaboration combines Pandion’s modular biologics and functional immunology expertise with Astellas' advanced therapeutics development and global commercialisation…
30 Oct 19
The EC approval is based on data from the Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy…